Prospective viewers should verify that accessing this content complies with applicable local regulations before purchase or viewing. Age restrictions apply in all jurisdictions, with verification requirements enforced by legitimate retailers.
| Model | Outcome | Notes | |-------|---------|-------| | | > 10 µM off‑target activity (clean) | Confirms selectivity | | Mouse AML xenograft (NSG, MOLM‑13) | Tumor regression (complete remission in 4/8 mice) | Oral dosing, BID, 25 mg/kg | | Syngeneic pancreatic cancer (KPC) + anti‑PD‑1 | 78 % TGI, increased CD8⁺ infiltration | Demonstrates immune‑modulating potential | | Rat toxicology (28‑day repeat dose) | NOAEL = 100 mg/kg/day | No observable cardiac, hepatic, or CNS toxicity | | Pharmacokinetics (PK) | Oral bioavailability ≈ 55 % in dogs; half‑life ≈ 12 h | Supports BID oral regimen | MEYD-873
4.5 / 5 Stars
